Strength: 100 mg/ml
Molecular Formula: C23H36O3,
Molecular Weight: 360.53014 g/mol
Active Ingredient: Drostanolone propionate
CAS number: 521-12-0
Dosage Form: Injectable, oil base sterile solution
Market Status: Prescription
Company: Hilma Biocare
Drostanolone Propionate 100 is a synthetic derivative of dihydrotestosterone, producing an
anabolic effect and promoting protein synthesis as well as creating positive nitrogen balance
in humans. Since it is a derivative of dihydrotestosterone, drostanolone does not aromatize
to estrogens. Drostanolone Propionate 100 has significant anabolic and androgenic
properties promoting an increase in 2 strength and growth of muscle tissue while acting as
an estrogen antagonist. The combination of a short-acting propionate ester with a longacting enanthate ester pro- duces rapid increases in serum drostanolone levels with a
sustained duration of 5-8 days.
Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and
adverse reactions demonstrate the androgenic properties of these drugs. Complete
dissociation of anabolic and androgenic effects has not been achieved. The actions of
anabolic steroids are thus similar to those of male sex hormones. Anabolic steroids suppress
the gonadotropic functions of the pituitary and may exert a direct effect upon the testes.
During exogenous administration of anabolic androgens, endogenous testosterone release
is inhibited through inhibition of pituitary luteinizing hormone (LH). At large doses,
spermatogenesis may be suppressed through feedback inhibition of pituitary
follicle-stimulating hormone (FSH).
Drostanolone aches to androgen receptors; increasing nitrogen retention and protein
synthesis. Drostanolone acts on DHT modulated pathways as well. Drostanolone is a potent
estrogen antagonist and does not aromatize estrogen, limiting expression of side effects
often linked to estrogen such as water retention, gynecomastia, and some types of high
blood pressure. Drostanolone undergoes hepatic metabolism with a half- life of 2-3 days
after separation of the ester.
To rapidly restore muscle tissue atrophied during recovery from a traumatic injury.
To offset muscle catabolism in patients with a wasting syndrome.
To treat certain types of anemia which are non-responsive to first line agents.
Oestrogen antagonist in treatment of breast cancer.
Not indicated for women, children, or the elderly. Women who are pregnant or may become
pregnant because of possible masculinization of the fetus.
Patients with nephrosis or the nephrotic phase of nephritis. Patients with hypercalcemia.
Patients suffering from testicular cancer, prostate cancer, breast cancer, liver damage,
kidney damage, stroke, high blood pressure, heart disease or respiratory problems.
Elevated liver enzymes and in rare cases hepatic liver dysfunction may occur. Periodic liver
function should be monitored for changes including serum bilirubin, AST, ALT, and AP.
Edema may be increased in patients on concurrent adrenal cortical steroid or ACTH therapy.
Anabolic steroid hormones may increase low-density lipoproteins (LDL) and decrease high
density lipoproteins (HDL).Lipids levels generally return to normal upon discontinuation of
treatment. Anabolic steroids may reduce clotting factors II, V, VII, and X, and may increase
prothrombin time (PT). Patients should be instructed to report any use of warfarin and any
Male: Gynecomastia, excessive frequency and duration of penile erections, oligospermia.
Skin and Appendages: Hirsutism, male pattern baldness and acne, gynecomastia.
Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Nausea, cholestatic jaundice, alterations in liver function tests; rarely, hepatocellular
neoplasms, peliosis hepatis, hepatic adenomas, and cholestatic hepatitis.
Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anticoagulant therapy.
Nervous System: Changes in libido, aggression, headache, anxiety, depression, and
Metabolic: reduced glucose tolerance, increased creatinine ance, and inhibition of
Serum lipid changes, hypercalcaemia, hypertension, oedema, priapism, and potentiation of
Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit, Hepatic function tests –
AST/ALT Prostatic specific antigen – PSA, Testosterone: total, free, and bioavailable.
Dihydrotestosterone & Estradiol. Male patients over 40 should undergo a digital rectal
examination and evaluate PSA prior to androgen use. Periodic evaluations of the 2 prostate
should continue while on androgen therapy, especially in patients with difficulty in es
urination or with changes in rlib voiding habits.
DOSAGE AND ADMINISTRATION
Adult male: 100 – 150 mg gonia injected IM every 3-5 days for a duration of 4-8 weeks.
Drostanolone Propionate 100 mg/ml, 10 ml multiple dose vial.
Store in a cool dry place between 15-25°C. Protect from light.